Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Design of antibody variable fragments with reduced reactivity to preexisting anti-drug antibodies.

mAbs - 1 Jan 2000

Johansson Maria U, Weinert Christopher, Reichardt Dietrich Alexander, Mahler Dana, Diem Dania, Hess Christian, Feusi Diana, Carnal Simon, Tietz Julia, Giezendanner Noreen, Spiga Fabio Mario, Urech David, Warmuth Stefan

Abstract excerpt

Upon reformatting of an antibody to single-chain variable fragment format, a region in the former variable/constant domain interface of the heavy chain becomes accessible for preexisting (PE) anti-drug antibody (ADA) binding. The region exposed because of this reformatting contains a previously hidden hydrophobic patch. In this study, mutations are introduced in this region to reduce PE ADA reactivity and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Development
Share to Mutation

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Single-Chain Antibodies

Source

Open in PubMed Open full text

Identifiers

PMID: 37312434
DOI: 10.1080/19420862.2023.2215887
PMCID: PMC10269415

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Design of antibody variable fragments with reduced reactivity to preexisting anti-drug antibodies.PMID 37312434Read ↗

A structure-based engineering approach to abrogate pre-existing antibody binding to biotherapeuticsSemantic proximity Read ↗

Structure-guided design of antibody CDRs to reduce their reactivity to treatment-emergent anti-drug antibodies.Semantic proximity Read ↗

Protein engineering approaches for antibody fragments: directed evolution and rational design approachesSemantic proximity Read ↗

Sequence features of variable region determining physicochemical properties and polyreactivity of therapeutic antibodiesSemantic proximity Read ↗

Intrinsic physicochemical profile of marketed antibody-based biotherapeuticsSemantic proximity Read ↗

Profiling the Biophysical Developability Properties of Common IgG1 Fc Effector Silencing VariantsSemantic proximity Read ↗

General strategy for the generation of human antibody variable domains with increased aggregation resistance.Semantic proximity Read ↗

Sagacious Epitope Selection for Vaccines, and Both Antibody-Based Therapeutics and Diagnostics: Tips From Virology and Oncology<strong> </strong>Semantic proximity Read ↗

Mutational landscape of antibody variable domains reveals a switch modulating the interdomain conformational dynamics and antigen binding.Semantic proximity Read ↗

OptMAVEn-2.0: De novo Design of Variable Antibody Regions against Targeted Antigen EpitopesSemantic proximity Read ↗

Identification of Engineered IMGT Fc Variants in IMGT/mAb-DB Therapeutic Antibodies and Fusion proteinsSemantic proximity Read ↗

Tuning antibody stability and function by rational designs of framework mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.